Dec 15, 2020 06:17AM

Dec 15, 2020 06:15AM

Dec 11, 2020 07:05AM

Dec 11, 2020 07:00AM

Dec 11, 2020 07:00AM

Nov 30, 2020 07:00AM

Nov 30, 2020 07:00AM Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia

Nov 30, 2020 07:00AM

Nov 18, 2020 07:02PM

Nov 18, 2020 07:01PM

Nov 13, 2020 07:00AM

Nov 13, 2020 07:00AM

Oct 27, 2020 07:09AM

Oct 27, 2020 07:00AM Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease

Oct 27, 2020 07:00AM

Sep 10, 2020 07:06AM

Sep 10, 2020 07:00AM

Sep 10, 2020 07:00AM

Aug 11, 2020 06:30AM

Aug 11, 2020 06:30AM

Jul 27, 2020 04:05PM Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006

Jul 27, 2020 04:05PM

Mar 26, 2020 07:00AM

Mar 26, 2020 07:00AM

Mar 24, 2020 07:03AM

Mar 24, 2020 07:00AM

Mar 24, 2020 07:00AM

Mar 2, 2020 07:05AM Prevail Therapeutics (PRVL) Announces IND Application Active for PR006 for Treatment of Frontotemporal Dementia with GRN Mutation

Mar 2, 2020 07:00AM

Mar 2, 2020 07:00AM

Feb 12, 2020 07:14AM

Feb 12, 2020 07:00AM

Feb 12, 2020 07:00AM

Jan 9, 2020 04:05PM

Jan 9, 2020 04:05PM Prevail Therapeutics Provides PR001 Program Update

Dec 26, 2019 08:32AM

Dec 26, 2019 08:30AM

Dec 26, 2019 08:30AM

Dec 16, 2019 04:06PM

Dec 16, 2019 04:05PM

Dec 16, 2019 04:05PM

Nov 12, 2019 09:30AM Prevail Therapeutics Reports Third Quarter 2019 Financial Results and Recent Business Highlights

Nov 12, 2019 09:30AM

Sep 10, 2019 04:10PM

Sep 10, 2019 04:05PM

Sep 10, 2019 04:05PM

Aug 14, 2019 07:00AM

Aug 14, 2019 07:00AM

Aug 7, 2019 04:00PM Prevail Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference

Aug 7, 2019 04:00PM

322,199 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All